Helus Pharma Inc. (NASDAQ:HELP) reported topline results from its pivotal Phase 3 APPROACH trial, showing its novel serotonergic agonist HLP003 rapidly and durably reduced symptoms in adults with major depressive disorder.
Chief Executive Officer Michael Halstead said patients with persistent depression symptoms face a major unmet need for fast-acting, well-tolerated adjunctive therapies.
Halstead emphasized that these trial results demonstrate a strong therapeutic profile and build momentum as the company advances HLP003 toward regulatory approval and potential commercialization.
HLP003 Achieves Rapid And Durable Depression Relief
The clinical-stage pharmaceutical company evaluated deuterated psilocin candidate HLP003 alongside existing antidepressants in 222 adults with moderate-to-severe depression. HLP003 achieved statistically significant and clinically meaningful gains across primary, key secondary, and other secondary endpoints.
At the six-week primary endpoint, HLP003 delivered a least squares mean reduction of 19.5 points from baseline in the MADRS total score, compared with 11.9 points for placebo.
Patients experienced rapid improvement as early as Day 2, when HLP003 reduced MADRS scores by 16.1 points versus 11.0 points for placebo. The therapy maintained this durability at the 12-week key secondary endpoint, posting a 16.9-point reduction compared with 9.9 points for placebo.
High Remission Rates And Favorable Safety Profile
HLP003 also produced superior response and remission rates at every measured interval, alongside significant improvements on the Clinical Global Impression Scale.
By six weeks, 56.3% of HLP003 patients achieved at least a 50% symptom reduction, while 50.9% reached remission, compared with 28.2% and 18.2% for placebo.
Roughly two-thirds of depression patients fail to achieve remission with first-line antidepressants.
Adding an adjunctive treatment helps clinicians enhance patient response without discontinuing existing medications or triggering withdrawal symptoms.
Patients generally tolerated HLP003 well, reporting mostly mild-to-moderate, transient adverse events on dosing day. Investigators recorded three treatment-related serious adverse events and identified no new safety signals.
Helus Pharma continues evaluating the therapy in the ongoing Phase 3 EMBRACE study, anticipating topline data in the fourth quarter of 2027, alongside the long-term EXTEND trial.
HELP Price Action: Helus Pharma shares were down 13.08% at $7.71 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock/ Pormezz
Recent Comments